S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The #1 Crypto for 2024 (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Secret Bull Market Starts in This Unusual Sector (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The #1 Crypto for 2024 (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Secret Bull Market Starts in This Unusual Sector (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The #1 Crypto for 2024 (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Secret Bull Market Starts in This Unusual Sector (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The #1 Crypto for 2024 (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Secret Bull Market Starts in This Unusual Sector (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Free Trial
NASDAQ:TALS

Talaris Therapeutics (TALS) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)
Free TALS Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$15.13
▼
$16.01
50-Day Range
$12.36
▼
$28.36
52-Week Range
$0.89
▼
$27.95
Volume
737,656 shs
Average Volume
386,531 shs
Market Capitalization
$660.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisCompetitorsDividendEarningsHeadlinesInsider TradesOwnershipSocial Media
TALS stock logo

About Talaris Therapeutics Stock (NASDAQ:TALS)

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.

TALS Stock News Headlines

February 25, 2024 | benzinga.com
Longitude Venture Partners III, L.P.'s Net Worth
November 1, 2023 | msn.com
Talaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15
April 20, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
October 19, 2023 | msn.com
Talaris Therapeutics goes ex-dividend tomorrow
October 18, 2023 | finanznachrichten.de
Talaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
October 17, 2023 | msn.com
Talaris shareholders approve merger, 1-for-10 reverse stock split
October 17, 2023 | finance.yahoo.com
Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio
October 6, 2023 | marketwatch.com
Shares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to Merger
April 20, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
October 6, 2023 | finance.yahoo.com
Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio
October 4, 2023 | finance.yahoo.com
New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics
September 12, 2023 | finance.yahoo.com
We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate
August 15, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOT
August 14, 2023 | finance.yahoo.com
ImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance Business
August 8, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURF
July 28, 2023 | benzinga.com
Moore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law Firm
July 27, 2023 | markets.businessinsider.com
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)
July 18, 2023 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMS
July 18, 2023 | msn.com
Talaris Therapeutics: Cashing Out Ahead Of Tourmaline Merger
July 6, 2023 | msn.com
Talaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75
June 27, 2023 | markets.businessinsider.com
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETI
June 26, 2023 | businesswire.com
TALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALS
June 23, 2023 | benzinga.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Talaris Therapeutics, Inc. Merger
June 23, 2023 | bizjournals.com
Talaris Therapeutics announces merger after layoffs
June 22, 2023 | bizjournals.com
NY biotech to go public by merging with Boston firm that laid off 95% of staff
June 22, 2023 | msn.com
Talaris jumps 29% on merger with Tourmaline Bio in all-stock deal
June 22, 2023 | markets.businessinsider.com
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR
See More Headlines
Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
4/20/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TALS
CUSIP
N/A
CIK
1827506
Web
talaristx.com
Phone
502-398-9250
Fax
N/A
Employees
84
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-73,890,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.93%
Return on Assets
-37.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.41
Quick Ratio
15.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.33 per share
Price / Book
3.57

Miscellaneous

Outstanding Shares
42,764,000
Free Float
35,708,000
Market Cap
$660.70 million
Optionable
Not Optionable
Beta
2.18
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

TALS Stock Analysis - Frequently Asked Questions

How were Talaris Therapeutics' earnings last quarter?

Talaris Therapeutics, Inc. (NASDAQ:TALS) announced its quarterly earnings results on Friday, November, 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03.

How often does Talaris Therapeutics pay dividends? What is the dividend yield for Talaris Therapeutics?

Talaris Therapeutics announced a dividend on Thursday, October 19th. Investors of record on Monday, October 16th will be given a dividend of $1.5118 per share on Friday, October 20th. The ex-dividend date is Friday, October 20th.
Read our dividend analysis for TALS.

When did Talaris Therapeutics IPO?

Talaris Therapeutics (TALS) raised $150 million in an initial public offering on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO.

This page (NASDAQ:TALS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
Your Money is Not Safe
American Alternative
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets